AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - AstraZeneca (NYSE:AZN)
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - HUTCHMED (China) (NASDAQ:HCM)